Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More - Yahoo Finance
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and Mo...
Danaher Said to Be Near $10 Billion Deal to Buy Masimo, FT Says - Bloomberg.com
Danaher Said to Be Near $10 Billion Deal to Buy Masimo, FT Says - Bloomberg.com
Danaher and Shanghai biotech company announce strategic partnership - China Daily
Danaher and Shanghai biotech company announce strategic partnership China Daily
Nuclera and Danaher-owned US ally boost protein proposition - Business Weekly
Nuclera and Danaher-owned US ally boost protein proposition Business Weekly
Introducing Cytiva: GE plans name change ahead of $21bn Danaher buy - BioProcess International
Introducing Cytiva: GE plans name change ahead of $21bn Danaher buy BioProcess International
‘Better together’ – Danaher completes Cytiva Pall merger - BioProcess International
‘Better together’ – Danaher completes Cytiva Pall merger BioProcess International
Danaher merging Cytiva and Pall - BioProcess Insider - BioProcess International
Danaher merging Cytiva and Pall - BioProcess Insider BioProcess International
Danaher Delivers: Cytiva, Pall Plan $1.5B Manufacturing Expansion - GEN - Genetic Engineering and Biotechnology News
Danaher Delivers: Cytiva, Pall Plan $1.5B Manufacturing Expansion GEN - Genetic Engineering and Biotechnology News
Cytiva rises out of GE Healthcare as Danaher completes $21bn deal - BioProcess International
Cytiva rises out of GE Healthcare as Danaher completes $21bn deal BioProcess International